tiprankstipranks
Advertisement
Advertisement

Compumedics Flags Record FY26 Results Despite Timing Delays, Positions for Stronger FY27

Story Highlights
  • Compumedics forecasts record FY26 revenue and EBITDA, driven by strong demand for sleep, neurology and MEG platforms alongside expanding SaaS and annuity revenues.
  • Revenue recognition is delayed by MEG installation timing, helium supply issues and a later Somfit D rollout, but cost controls, liquidity and a U.S. reset aim to support earnings and FY27 growth conversion.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Compumedics Flags Record FY26 Results Despite Timing Delays, Positions for Stronger FY27

Claim 55% Off TipRanks

The latest update is out from Compumedics Limited ( (AU:CMP) ).

Compumedics reported sustained order momentum across its sleep, neurology and MEG platforms, underpinned by growing SaaS and annuity revenues that improve visibility and the quality of future income. The company expects record revenue of about $62 million to $65 million and record EBITDA of $5.5 million to $7 million in FY26, representing strong year-on-year growth despite operational headwinds.

Management highlighted that revenue conversion has lagged order intake due to shipment and installation timing for MEG systems and a deliberate delay to the Somfit D rollout in the U.S., compounded by helium supply constraints linked to Middle East conflict. These issues are framed as timing-related, with revenues anticipated to flow more strongly into FY27, while disciplined cost control, a U.S. cost base reset and enhanced working capital facilities provide earnings resilience and liquidity.

In the core Sleep and Neurology business, connected platforms continue to gain traction, including deeper integration into pharmaceutical and contract research organization ecosystems, supporting a larger installed base and recurring income. However, U.S. capital equipment performance remains below expectations, prompting leadership changes and a targeted commercial reset, with the Somfit D launch expected to help restore momentum in this key market.

More about Compumedics Limited

Compumedics Limited operates in the medical technology sector, focusing on sleep diagnostics, neurology monitoring and magnetoencephalography (MEG) systems. The company is also expanding software-as-a-service and annuity-based connected platforms, including its Somfit and Nexus 360 offerings, targeting recurring revenue streams in sleep and neurology markets globally.

Average Trading Volume: 72,435

Technical Sentiment Signal: Sell

Current Market Cap: A$54.93M

For an in-depth examination of CMP stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1